Literature DB >> 1676275

Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.

F D Tóth1, B Szabó, E Ujhelyi, K Pálóczi, A Horváth, G Füst, J Kiss, D Bánhegyi, S R Hollán.   

Abstract

Reclustering and indirect immunofluorescence assays on MT-4 cells [carrying both CD4 and complement receptor type 2 (CR2)] were used to measure neutralizing and enhancing antibodies in sera obtained from HIV-1-infected individuals. Heat-inactivated sera were tested before and after mixing 1:1 with fresh seronegative human serum. Using heated samples, neutralizing antibodies were found in 20 out of 20 and 11 out of 19 serum samples of asymptomatic and symptomatic [AIDS, AIDS-related complex (ARC)] HIV-seropositive patients, respectively. In complement-restored samples, neutralizing activity was found in eight sera of asymptomatic patients and in none of the sera of AIDS and ARC patients; enhancing activity could be detected in four and 12 sera, respectively. A significant positive correlation was observed between the titres of neutralizing antibodies measured in the complement-restored samples and the absolute number of CD4+ lymphocytes. These findings indicate that the appearance of complement-dependent enhancing antibodies coincident with the loss of neutralizing antibodies may indicate a poor prognosis in HIV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676275     DOI: 10.1097/00002030-199103000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41.

Authors:  T Hidvégi; Z Prohászka; E Ujhelyi; N M Thielens; M P Dierich; H Hampl; G Arlaud; K Nagy; G Füst
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

5.  Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Authors:  Zoltán Prohászka; Ferenc D Tóth; Dénes Bánhegyi; George Füst
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

6.  Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  D C Montefiori; B S Graham; S Kliks; P F Wright
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

7.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

Authors:  C F Ebenbichler; N M Thielens; R Vornhagen; P Marschang; G J Arlaud; M P Dierich
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

Review 8.  Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

9.  Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.

Authors:  S B Jiang; K Lin; A R Neurath
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

Review 10.  Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development.

Authors:  Zoltán Beck; Zoltán Prohászka; George Füst
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.